BBOT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
60.2M
+30.3%
46.2M
+6.4%
43.4M
-11.7%
49.2M
R&D
49.2M
+23.7%
39.8M
+4.5%
38.1M
+8.6%
35.1M
SG&A
11.0M
+71.9%
6.4M
+19.6%
5.3M
-62.2%
14.1M
Operating Income
-60187000
-30.3%
-46179000
-6.4%
-43408000
+11.7%
-49181000
EBITDA
-59996000
-30.4%
-45993000
-7.0%
-42994000
+12.2%
-48985000
Net Income
-56454000
-34.1%
-42106000
-8.5%
-38797000
+13.3%
-44757000
EPS (Basic)
$-705.20
-34.0%
$-526.11
-109506.3%
$-0.48
+53.4%
$-1.03
EPS (Diluted)
$-705.20
-34.0%
$-526.11
-109506.3%
$-0.48
+53.4%
$-1.03
Shares (Diluted)
80.1K
+0.0%
80.0K
-99.9%
80.6M
+85.4%
43.5M
BridgeBio Oncology Therapeutics (BBOT) โ€” Financials